H.C. Wainwright analyst Raghuram Selvaraju downgraded Aardvark Therapeutics (AARD) to Neutral from Buy without a price target The ARD-101 pivotal Prader-Willi syndrome trial was paused out of caution following cardiac observations in open-label dosing, the analyst tells investors in a research note. The firm says it does not have visibility on the fate of the ARD-201 program.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark downgraded to Equal Weight from Overweight at Morgan Stanley
- Aardvark downgraded to Sector Perform from Outperform at RBC Capital
- Aardvark Therapeutics downgraded to Hold from Buy at Stifel
- Aardvark Pauses ARD-101 Phase 3 HERO Trial Enrollment
- Aardvark Therapeutics down 54% to $5.70 after pausing Phase 3 HERO trial